Chemkart India Ltd

Chemkart India Ltd has filed a revised disclosure regarding insider trading regulations. Shailesh Vinodrai Mehta, a promoter and designated person, acquired 1,800 equity shares, representing 0.01% of the company's paid-up equity share capital. The acquisition took place on July 1, 2026, via on-market purchase. This filing is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, specifically Regulation 7(2)(a) and 7(2)(b), requiring disclosure of changes in holding by promoters and designated persons.

Chemkart India Ltd has filed disclosures regarding insider trading regulations. Shailesh Vinodrai Mehta, identified as a Promoter, has acquired 1,800 equity shares, representing 0.01% of the company's paid-up equity share capital. This acquisition was made on the open market on July 1, 2026. The filing is in compliance with Regulation 7(2)(a) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and submitted as per Regulation 7(2)(b). The company has requested that these disclosures be taken on record.

Shailesh Vinodrai Mehta, a promoter of Chemkart India Limited, has acquired 10,800 equity shares of the company through open market acquisition on BSE Limited. The transaction, dated June 24, 2026, involved shares with a face value of INR 10/-. Following this acquisition, Mr. Mehta's total shareholding increased from 1.08% to 1.17%. The company's equity share capital remains unchanged at INR 12,09,90,000, comprising 1,20,99,000 equity shares of Rs. 10/- each.

Chemkart India Limited has filed disclosures regarding an acquisition of equity shares by Shailesh Vinodrai Mehta, a designated person. Mr. Mehta acquired 10,800 equity shares, representing 0.09% of the company's paid-up equity share capital. The acquisition was made through a purchase on the stock exchange. The filing is in compliance with Regulation 7(2)(a) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The company has requested that these disclosures be taken on record.

Chemkart India Ltd has invested ₹10 Lakhs in its wholly owned subsidiary, Vinstar Biotech Private Limited, through a rights issue. The investment was made by subscribing to 1,00,000 equity shares at face value. This capital infusion is intended for Vinstar Biotech's capital expenditure and working capital requirements. Vinstar Biotech is an R&D-driven nutraceutical company specializing in proprietary bioactive technologies. The transaction is considered a related party transaction but is conducted at arm's length. Vinstar Biotech's financials as of March 31, 2026, show a turnover of ₹223.43 Lakhs, a loss after tax of ₹(24.72) Lakhs, and a net worth of ₹(34.69) Lakhs. Chemkart's shareholding in Vinstar Biotech remains at 100% post-investment.

Chemkart India Ltd has filed disclosures regarding the acquisition of equity shares by a designated person, Jaini Shailesh Mehta. The filing, made under SEBI (Prohibition of Insider Trading) Regulations, 2015, details the acquisition of 1,200 equity shares on June 12, 2026, representing 0.01% of the paid-up equity share capital. This disclosure is a routine compliance requirement for significant changes in shareholding by insiders.

Jaini Shailesh Mehta, part of the Promoter Group of Chemkart India Ltd, has acquired 2,400 equity shares of the company through open market transactions on BSE Limited on June 12, 2026, and June 18, 2026. This acquisition represents a minor increase in the promoter group's shareholding, bringing their total stake to 0.03% post-acquisition. The total equity share capital of the company remains unchanged at INR 12,09,90,000, comprising 1,20,99,000 equity shares.

Chemkart India Ltd has invested ₹1.00 Crores in its wholly-owned subsidiary, Easy Raw Materials Private Limited, through a rights issue. This investment, comprising 10,00,000 equity shares at face value, is part of the utilization of IPO proceeds to commission the subsidiary's manufacturing unit. Easy Raw Materials Private Limited is involved in trading pharma products and nutritional supplements. The subsidiary reported NIL turnover, a loss after tax of ₹59.47 Lakhs, and a net worth of ₹578.60 Lakhs as of March 31, 2026. Chemkart's shareholding in the subsidiary remains at 100%.

Chemkart India Ltd. has confirmed no deviations or variations in the utilization of IPO proceeds for the half-year ended March 31, 2026, as per Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Audit Committee reviewed and the Board of Directors recorded the statement on May 18, 2026. The IPO raised ₹64.48 Crores on July 9, 2025, with net proceeds of ₹54.68 Crores utilized for capital expenditure, debt repayment, and general corporate purposes. Brickwork Ratings India Private Limited served as the monitoring agency.

Chemkart India Ltd has appointed M/s Vinay Bhushan & Associates as the Internal Auditor for the financial year ending March 31, 2027, based on the Audit Committee's recommendation. The appointment was approved at the Board of Directors meeting held on May 18, 2026. Additionally, the Board approved the audited standalone and consolidated financial results for the year ended March 31, 2026, with an unmodified opinion from Statutory Auditors M/s. Bagaria & Co. LLP.